Gastroprotective Medication and Bleeding Risk Following ACS
Patients with high bleeding risk taking DAPT were not routinely provided with GI prophylaxis. Increased use of objective bleeding risk scores may help guide risk/benefit decisions in patients taking clopidogrel who are considered for PPIs. Further research on the safety and efficacy of PPIs for the primary prevention of GI bleeding in patients taking DAPT is warranted.
Conclusion
Patients with high bleeding risk taking DAPT were not routinely provided with GI prophylaxis. Increased use of objective bleeding risk scores may help guide risk/benefit decisions in patients taking clopidogrel who are considered for PPIs. Further research on the safety and efficacy of PPIs for the primary prevention of GI bleeding in patients taking DAPT is warranted.
SHARE
